Table 3.
Markers to distinguish mature NK cell tumors (ANKL, ENKTL, NK-CLPD) and reactive NK lymphocytosis (RNKL).
| ①ANKL N = 14 | ②ENKTLN = 23 | ③NK-CLPD N = 8 | ④RNKLN = 10 | P value | ||||
|---|---|---|---|---|---|---|---|---|
| (①vs.④) | (②vs.④) | (③vs.④) | ||||||
| Abnormal expression or loss of T-series generic markers (CD2、CD4、CD5、CD7) | 8 (57.14) a | 15 (65.22) b | 5 (62.50) c | 4 (40.00) d | 0.680 | 0.257 | 0.637 | |
| CD16 is uniformly lost or attenuated | 10 (71.43) | 20 (86.96) | 2 (25.00) | 1 (10.00) | 0.005* | <0.001* | 0.559 | |
| Strong CD56 expression | 7 (50.00) | 10 (43.48) | 1 (12.50) | 0 | 0.019* | 0.015* | 0.444 | |
| CD57 is uniformly lost | 13 (92.86) | 16 (69.57) | 5 (62.50) | 2 (20.00) | <0.001* | 0.020* | 0.145 | |
| Abnormal expression of CD45RA and CD45RO | 9 (64.29) | 7 (30.43) | 1 (12.50) | 0 | 0.002* | 0.073 | 0.444 | |
| HLA-DR positive or weak positive | 14 (100.00) | 19 (82.61) | 6 (75.00) | 3 (30.00) | <0.001* | 0.006* | 0.153 | |
| None KIRs expression | 12 (85.71) | 13 (56.52) | 5 (62.50) | 3 (30.00) | 0.010* | 0.259 | 0.342 | |
| Granzyme B and/or Perforin negative | 12 (85.71) | 13 (56.52) | 2 (25.00) | 1 (10.00) | 0.001* | 0.021* | 0.559 | |
| Ki-67 or PD-1 or CD30 expression | 9 (64.29) | 17 (73.91) | 3 (37.50) | 1 (10.00) | 0.013* | 0.001* | 0.275 | |
a, All 8 cases had loss or weak expression of CD7. b, CD7 was lost or weakly expressed (11 cases); CD2 was lost (2 cases); CD4 was expressed (1 case); CD4 expression was accompanied by CD7 loss (1 case). c, CD7 was lost or weakly expressed (4 cases); CD5 expression with weak CD7 expression (1 case). d, CD5 expression with diminished CD7 expression (3 cases); CD7 loss (1 case). *P-value less than or equal to 0.05 was considered statistically significant.